Daily non-political popular news in brief.

Researchers propose reason for severe side-effects of Northwick Park clinical trial

A possible reason why the Northwick Park clinical trial of the drug TGN1412 in the UK caused multiple organ failure in human volunteers is revealed in research presented today at a conference near Paris. The research shows that stimulating the molecule CD28 on cells that mediate the immune response, known as T cells, can have an adverse effect if these immune cells have been activated and altered by infection or illness in the past.

Read more »

Keywords: researchers, propose, reason, severe, side-effects, northwick, park, clinical, trial, researcher, side, effects

« Previous | Next »

Similar news on "Researchers propose reason for severe side-effects of Northwick Park clinical trial":

1. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
   09-10-2007 · EurekAlert!
   Researchers have found surprising evidence that an antidepressant (citalopram) may perform as well as a commonly prescribed antipsychotic (risperidone) in the alleviation of severe agitation and psychotic symptoms of dementia. Researchers also found that the antidepressant was associated with "significantly lower" adverse side effects.
   Similar news · Read more »
   
2. The more we get, the more we need: Study shows how to prevent morphine 'tolerance'
   11-01-2007 · EurekAlert!
   Tolerance to the pain-relieving effects of morphine -- which builds rapidly with prolonged use -- can be prevented by blocking a substance that's formed when the drug is taken, researchers at Saint Louis University have discovered. Their findings could lead to new therapies that allow morphine to be administered without patients becoming tolerant of it -- a significant obstacle to effective pain relief -- nor experiencing a host of severe side effects that accompany escalating doses of the painkiller.
   Similar news · Read more »
   
3. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
   01-22-2008 · EurekAlert!
   After transplant surgery, antirejection drugs for the organ recipient are a must. But prolonged use can have serious side effects, including infections, heart disease and even cancer. A team of researchers at Northwestern University's Feinberg School of Medicine is working with Northwestern Memorial Hospital's department of organ transplantation in a new study that seeks to eliminate the need for antirejection drugs by transplanting stem cells from a kidney donor's bone marrow into the organ recipient.
   Similar news · Read more »
   
4. MIT brace aids stroke recovery
   03-22-2007 · EurekAlert!
   At age 32, Maggie Fermental suffered a stroke that left her right side paralyzed. After a year and a half of conventional therapy with minimal results, she tried a new kind of robotic therapy developed by MIT engineers. A study to appear in the April 2007 issue of the American Journal of Physical Medicine & Rehabilitation shows that the device, which helped Fermental, also had positive results for five other severe stroke patients in a pilot clinical trial.
   Similar news · Read more »
   
5. Ireland Cancer Center researchers advance stem cell gene therapy
   12-12-2007 · EurekAlert!
   Ireland Cancer Center of University Hospitals Case Medical Center researchers recently made great strides in stem cell gene therapy research by transferring a new gene to cancer patients, via their own stem cells, with the ultimate goal of being able to use stronger chemotherapy treatment with less severe side effects. This is the first time selection of this gene has been shown to occur in patients.
   Similar news · Read more »
   
6. Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema
   02-11-2008 · EurekAlert!
   Researchers at Pulmonary Associates today announced the start of the EASE Trial, a multicenter clinical trial to explore Airway Bypass, an investigational treatment that may offer a new, minimally invasive option for those suffering with advanced widespread emphysema.
   Similar news · Read more »
   
7. New cements for vertebral lesions
   02-07-2008 · EurekAlert!
   A number of researchers at the Department of Polymer Science and Technology at the Chemistry Faculty from San Sebastian at the University of the Basque Country, led by Ms Isabel Goni and Ms Marilo Gurrutxaga, are studying new formulae for acrylic copolymers and compounds in order to obtain efficacious, multiuse bone cements with reduced side effects.
   Similar news · Read more »
   
8. Promising Antiobesity Drug Fails To Produce Clinically Meaningful Weight Loss
   10-05-2006 · ScienceDaily
   A drug designed to target a powerful hunger-stimulating factor that has long been considered a prime target for antiobesity therapy failed to produce clinically meaningful weight loss in obese people in a long-term clinical trial. People taking the drug known as MK-0557 for a year consistently lost about three pounds more than those taking a placebo, researchers reported in the October issue of the journal Cell Metabolism, published by Cell Press.
   Similar news · Read more »
   
9. New data show ACTOS(r) (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
   11-13-2006 · EurekAlert!
   Researchers today presented data showing that ACTOS® (pioglitazone HCl) halted the progression of atherosclerosis as measured by carotid intima-media thickness (CIMT) in patients with type 2 diabetes. Results from the clinical trial, CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), are part of a late-breaker presentation at the American Heart Association's Scientific Sessions 2006, coincidentally being held in Chicago, and coincide with an early online issue of the Journal of the American Medical Association.
   Similar news · Read more »
   
10. First clinical trial of gene therapy for childhood blindness
    05-01-2007 · EurekAlert!
    The first clinical trial to test a revolutionary treatment for blindness in children has been announced by researchers at UCL (University College London). The trial, funded by the Department of Health, is the first of its kind and could have a significant impact on future treatments for eye disease.
    Similar news · Read more »